Pharmacodynamics of CT-P39, a Proposed Biosimilar of Omalizumab, Comparing with EU-Xolair and US-Xolair; Result of a Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study in Healthy Subjects-MedSci.cn

Pharmacodynamics of CT-P39, a Proposed Biosimilar of Omalizumab, Comparing with EU-Xolair and US-Xolair; Result of a Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study in Healthy Subjects

Mclendon, K; Wabnitz, P; Kim, SH; Ahn, KY; Kim, SY; Heo, GJ; Ka, JE; Choi, JI

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022; 149 (2): AB195

科室
- - 订阅+
  - 更多科室
工具
服务